Pfizer (PFE) Cash & Equivalents (2009 - 2026)

Pfizer (PFE) has reported Cash & Equivalents for 18 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 19.09% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (up 19.09% YoY), while the FY2025 annual figure was $1.1 billion, up 9.49% from the prior year.
• Cash & Equivalents improved to $1.7 billion in Q1 2026 per PFE's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $2.9 billion in Q4 2023 and bottomed at $416.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $1.6 billion across 5 years, with a median of $1.4 billion in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 78.6% — and 2023, when it jumped 585.82%.
• Pfizer's Cash & Equivalents stood at $416.0 million in 2022, then surged by 585.82% to $2.9 billion in 2023, then tumbled by 63.44% to $1.0 billion in 2024, then gained by 9.49% to $1.1 billion in 2025, then jumped by 49.12% to $1.7 billion in 2026.
• Business Quant data shows PFE's Cash & Equivalents at $1.7 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.